Final Preclinical Asthma Study Confirms Efficacy
December 11, 2017 19:24 ET
|
Cynata Therapeutics Limited
Clear confirmation of efficacy of Cynata’s proprietary Cymerus™ MSCs in second preclinical asthma studyTreatment with Cymerus MSCs in clinically-relevant model caused significantly greater reduction...
Enrolment of First Cohort Completed with Eighth Participant Dosed in Cynata’s World First Clinical Trial
November 15, 2017 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress...
Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
September 05, 2017 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today it will be featured as a...
Positive Data from Cynata MSCs in Second Preclinical Asthma Study
August 23, 2017 08:00 ET
|
Cynata Therapeutics Limited
Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthmaCymerus MSCs caused significantly greater reduction of airway...
FDA Meeting Provides Clear Path for Cynata US Development Plans
July 05, 2017 09:48 ET
|
Cynata Therapeutics Limited
Cynata Pre-IND meeting with the US FDA completed successfullyFDA confirms Cymerus™ manufacturing dossier meets expectationsClear path determined for preclinical and clinical protocol requirements for...
Cynata Therapeutics Files New Patent Application for Cymerus™ Stem Cell Technology in Oncology
June 20, 2017 11:18 ET
|
Cynata Therapeutics Limited
Application filed with IP Australia would expand patent estate to immunotherapyCreates new opportunities in the growing field of immunotherapy and reinforces a position in oncology MELBOURNE,...